Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study-Reference-Cited by-同舟云学术

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

Published:2004-03-04 Issue:5 Volume:18 Page:989-997
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Holowiecki J, ,Grosicki S,Robak T,Kyrcz-Krzemien S,Giebel S,Hellmann A,Skotnicki A,Jedrzejczak W W,Konopka L,Kuliczkowski K,Zdziarska B,Dmoszynska A,Marianska B,Pluta A,Zawilska K,Komarnicki M,Kloczko J,Sulek K,Haus O,Stella-Holowiecka B,Baran W,Jakubas B,Paluszewska M,Wierzbowska A,Kielbinski M,Jagoda K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2403336.pdf

Reference43 articles.

1. Rees JK, Gray G, Wheatley K . Dose intensification in acute myeloid leukemia: great effectiveness at lower cost. Principal report of a Medical Research Council's AML 9 study. Br J Haematol 1996; 94: 89–94.

2. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT vs ADE as induction chemotherapy in children and young adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML trials (MRC AML 10). Blood 1997; 89: 2311–2318.

3. Yates J, Glidewell OJ, Wiernik P, Cooper MR, Steinberg D, Dosik H et al. Cytosine arabinoside with daunorubicin or adriamycin therapy with acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454–463.

4. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S et al. Randomized multi-center trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990; 4: 177–183.

5. Lowenberg B, Sucio S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R et al. Mitoxantrone vs daunorubicin in induction–consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission as well as in assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report of the EORTC LCG-HOVON randomised phase III study AML-9. J Clin Oncol 1998; 16: 1–11.

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience;Frontiers in Oncology;2024-05-21

2. Exploration of novel 6,8,9-trisubstituted purine analogues: synthesis, in vitro biological evaluation, and their effect on human cancer cells;Turkish Journal of Chemistry;2024-02-21

3. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis;Medicine;2023-11-03

4. The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients;Cancers;2023-09-09

5. Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia;American Journal of Hematology;2023-08-27